70 likes | 189 Views
IHPI Partnerships. Robert M. Merion, MD, FACS President, Arbor Research Collaborative for Health Professor of Surgery, University of Michigan May 26, 2011. Advancing Medicine and Promoting Health. Typical pathways to research ideas and funding Investigator-initiated RFP-driven
E N D
IHPI Partnerships Robert M. Merion, MD, FACS President, Arbor Research Collaborative for Health Professor of Surgery, University of Michigan May 26, 2011
Advancing Medicine and Promoting Health • Typical pathways to research ideas and funding • Investigator-initiated • RFP-driven • Mechanisms to support research • Traditional grants • Research contracts • Philanthropy • Conventional wisdom • Grants mainly lead to manuscripts • Research contracts mainly lead to reports • Disseminating new knowledge and changing practice is challenging, expensive, and foreign to many of us
Dynamic Relationships Industry/Consortium Research Contracts Traditional Grants (R01, U01) Peer-reviewed Manuscripts Changes in Practice Intended and Unintended Consequences Government Research Contracts Changes in Policy/Reimbursement
Looking for Synergy Industry/Consortium Research Contracts Traditional Grants (R01, U01) Peer-reviewed Manuscripts Changes in Practice Government Research Contracts Changes in Policy/Reimbursement
Study of Medicare Payment Reform andHealth Disparities in Renal Dialysis • NIH R01 grant awarded to Arbor Research by National Institute of Minority Health and Health Disparities (2011-2015) • Study effects of the new Medicare Prospective Payment System (PPS) for dialysis services on health disparities • Risk for health disparity groups due to differences in treatment costs not captured by PPS (Black, rural) • Examine changes in clinical outcomes, access to care, and clinical processes of care • Combines data collected for the Dialysis Outcomes and Practice Patterns Study (DOPPS) with Medicare data
Combining Two Complementary Data Sources • Dialysis Outcomes and Practice Patterns Study (DOPPS) • International study (12 countries) coordinated by Arbor Research • Representative, random sample of dialysis facilities • 4,500 patients, 140 US dialysis facilities • Key strengths: • Timely data (~4 month lag) • Detailed treatment practices & outcomesin hemodialysis • Pre-dialysis care • Extensive comorbid conditions • Use of medications • Lab values • Quality of life • Medicare • Administrative data for all Medicare dialysis patients from CMS • 330,000 patients, 5,000 dialysis facilities • Key strengths: • Includes most US dialysis patients (diagnosis of renal failure is a basis for Medicare eligibility) • Statistical power • All types of dialysis • Key quality indicators • Utilization of services and clinical diagnoses from claims • Hospitalization • Evaluation of health disparities